Synopsis

Source of validity: Scientific
Rating (out of 5): 2

S-adenosyl-L-methionine (SAMe) has been studied as a treatment for Fibromyalgia Syndrome (FMS), primarily due to its potential effects on mood, pain perception, and inflammation. SAMe is a naturally occurring compound involved in methylation reactions in the body and plays a role in neurotransmitter synthesis, which has relevance since many FMS patients experience depression and chronic pain. Several small clinical trials and meta-analyses have evaluated the efficacy of SAMe in fibromyalgia, with mixed but generally modestly positive results.

A 2010 systematic review (Altern Ther Health Med, 2010) and earlier randomized controlled trials found that SAMe supplementation (oral or parenteral) led to improvements in pain, fatigue, and mood symptoms compared to placebo. However, these studies were generally small, short-term, and some had methodological limitations. The effect sizes reported have been modest, and replication in larger, well-controlled trials is lacking.

SAMe’s mechanism in FMS may be related to its role in increasing levels of serotonin and dopamine, neurotransmitters involved in pain modulation and mood regulation. While some clinical guidelines mention SAMe as a possible adjunct for FMS, it is not considered a first-line therapy. The overall evidence, while present, remains limited (rated 2/5), and more robust, larger-scale studies are needed to establish its efficacy and safety for this indication.

More about SAMe (s-adenosyl-l-methionine disulfate p-toluensulfate)
More about Fibromyalgia Syndrome

Other ingredients used for Fibromyalgia Syndrome

Other health conditions supported by SAMe (s-adenosyl-l-methionine disulfate p-toluensulfate)

Products containing SAMe (s-adenosyl-l-methionine disulfate p-toluensulfate)

Metagenics Blisphora®
Douglas Laboratories SAM-e
Designs For Health SAMe
Designs For Health SAMe
Pure Encapsulations SAMe (S-Adenosylmethionine)